Additionally, the tumor microenvironment can exert immunosuppressive effects that hinder the efficacy of neoantigen-targeted therapies, necessitating the exploration of combination strategies that include immune checkpoint inhibitors or other modalities to enhance anti-tumor immunity [Author, Year].